Extended Zerlasiran Data Show Sustained Lp(a) Reduction

The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.

Related Keywords

New York ,United States ,Cleveland ,Ohio ,Stevene Nissen ,Roberts Rosenson , ,Icahn School Of Medicine At Mount Sinai ,Cleveland Clinic ,Silence Therapeutics ,Icahn School ,Mount Sinai ,New York City ,Lipids ,Ipid Management ,Vldl Cholesterol ,Low Density Lipoprotein Cholesterol ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Artery Disease ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,Double Blind Studies ,